At the beginning of this decade,many pharmaceutical companies had development programs focused on delivering“new and improved” PPAR agonists to the market.For example, several programs were developing PPAR-α/γ dual agonists (i.e., glitazars) for thetreatment of type 2 diabetes. The gene discussed is PPARA; the disease is type 2 diabetes mellitus.